New CRISPR-based assay can non-invasively detect a biomarker of acute kidney rejection in urine

When a patient receives a kidney transplant, doctors carefully monitor them for signs of rejection in several ways, including biopsy. However, this procedure is invasive and can only detect issues at a late stage.